BDRX - Biodexa Pharmaceuticals Plc Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BDRX

BIODEXA PHARMACEUTICALS PLC

NASDAQ

$0.87

▼ DOWN 3.54% (-0.03)

KEY STATISTICS

Market Cap$647.70 K

52w High$59.40

52w Low$0.83

Dividend Yield—

Frequency—

P/E-1033.45

Volume103.70K

Shares Out.746.11K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Stephen Anthony Stamp

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 7, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateSep 11, 2026

DayFriday

Rev. Est.—

SEP

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-07-29	Reverse	1:10000
2026-04-06	Reverse	1:5
2025-07-31	Reverse	1:10
2024-10-04	Reverse	1:25
2023-07-05	Reverse	1:80
2023-03-27	Reverse	1:4
2022-09-26	Reverse	1:5
2020-03-03	Reverse	1:5
2019-04-08	Reverse	1:10
2018-01-02	Forward	507:500

PRICE

$0.87 ▼ DOWN 3.54% (−$0.03)

OVERLAYS

About Biodexa Pharmaceuticals Plc

https://www.biodexapharma.com ↗

Biodexa Pharmaceuticals Plc, a UK-based clinical-stage biopharma, develops therapies for familial adenomatous polyposis, bladder cancer, Type 1 diabetes, and rare brain cancers, with lead candidates Tolimidone and MTX110 in Phase II and I trials.

INDUSTRY

Biotechnology

A PRODUCT BIODEXA PHARMACEUTICALS PLC IS KNOWN FOR

eRapa™

eRapa, an oral rapamycin tablet for familial adenomatous polyposis (FAP), is in Phase 3 trials, with Orphan Drug Designation from the European Commission, aiming to treat a rare condition that increases colorectal cancer risk.